Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

PETNET Solutions signs EU manufacturing agreement with Lilly for Amyvid radiopharmaceutical

Siemens Healthcare USA : 04 June, 2013  (Company News)
PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, is to begin manufacturing Eli Lilly's Amyvid(Florbetapir (18F)) radiopharmaceutical in the United Kingdom, as well as in Spain and France, after signing a manufacturing services agreement with Eli Lilly.


Siemens' PETNET Solutions will function as a contract manufacturer for Lilly after Lilly's diagnostic radiopharmaceutical received marketing authorisation from the European Commission in early 2013.



Amyvid (Florbetapir (18F)) solution for injection is a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation. The first commercial doses of Amyvid produced by Siemens' PETNET Solutions are expected to begin in the UK this summer. Commercial supply from Siemens' PETNET Solutions locations in Spain and France is expected to start by the end of 2013 and in 2014, respectively, pending regulatory approval of these sites.



The manufacturing agreement with Lilly follows significant investments by Siemens' PETNET Solutions to standardise equipment and processes throughout its global network, including new automated processes and redundant equipment to serve clinical research demands and immediate patient needs. Siemens' PETNET Solutions is already the largest manufacturer and distributor of Amyvid in the United States.

 

"This agreement with Lilly is another proof point that Siemens is at the forefront of providing leading PET imaging solutions to fight against the most challenging diseases such as Alzheimer's disease," said Dr Christoph Zindel, Chief Executive Officer of PETNET Solutions. "With our investments into our network over the last several years and our experience manufacturing Amyvid in the USA, we are confident that we will provide our customers in Europe the same level of high delivery reliability as our customers have come to expect from PETNET Solutions."


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo